Cat. No.: HY-146064

OPN-IN-1

9 Cited Publications

Customer Review

Based on 9 publication(s) in Google Scholar

OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 2257492-95-6
Formula: C₂₅H₃₃N₃O₅
Molecular Weight:455.55

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

OPN-IN-1 Chemical Structure

CAS No.: 2257492-95-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Publications (9)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer^[1].

In Vitro

OPN-IN-1 (Compound 11) (50 μM; 24 h) can inhibit the expression of osteopontin (OPN) in MDA-MB-435 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-435
Concentration:

50 μM
Incubation Time:

24 h
Result:

Decreased OPN expression by ~ 0.3 fold.

Chemical Information

CAS No. 2257492-95-6
Appearance Solid
Molecular Weight 455.55
Formula C₂₅H₃₃N₃O₅
Color White to yellow
SMILES

[H][C@@]12CC[C@]3(OO[C@]14[C@@H](O3)OC([C@@H]([C@@]4(CC[C@H]2C)[H])C)OCC5=CN(N=N5)CC6=CC=CC=C6)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All WBCell Migration/Invasion AssayCell Proliferation/Viability AssayIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

2025 Dec 26.

OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.

OPNi-1 (50 μM, 24 h) decreased the protein expression of YKL40, EFEMP-1, and CD44 in BNI_2-4 cells after culture with hypoxic conditioned medium derived from THP-1 and U937.

OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.

OPNi-1 (50 μM, 48 h) decreased cell migration in BNI_2-4 cells after culture with hypoxic conditioned medium derived from THP-1 (L) and U937.

OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.

OPNi-1 (50 μM, 48 h) inhibited cell growth of BNI_2-4 cells following culture with hypoxic conditioned medium from THP-1 (L) and U937.

OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.

OPNi-1 (0.5 mg/kg, intraperitoneal injections, 5 consecutive days followed by a 2-day drug holiday, and repeat the cycle) inhibited tumor growth compared with the control treatment in an orthotopic mouse model of GBM using GL261 cells in C57BL/6J mice.

OPN-IN-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Dec 26.

OPNi-1 (0.5 mg/kg, intraperitoneal injections, 5 consecutive days followed by a 2-day drug holiday, and repeat the cycle) reduced PD-L1 expression in an orthotopic mouse model of GBM using GL261 cells in C57BL/6J mice.
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2024 Dec 5:e2410360. PMID: 39639496
J Neuroinflammation

Lateralized response of skull bone marrow via osteopontin signaling in mice after ischemia reperfusion. [Abstract]

2023 Dec 9;20(1):294. PMID: 38071333
J Inflamm (Lond)

The injury effect of osteopontin in sepsis-associated lung injury. [Abstract]

2025 Jan 24;22(1):4. PMID: 39856697
Int Immunopharmacol

USP22/BRD4 mediated hedgehog pathway activation contributes to airway remodeling in asthma. [Abstract]

2025 Mar 24:153:114538. PMID: 40132456
Biol Direct

Macrophage-derived SPP1 exacerbate myocardial injury by interacting with fibroblasts in viral myocarditis. [Abstract]

2025 Mar 14;20(1):30. PMID: 40087693
Brain Res Bull

Osteopontin inhibitor alleviates neuroinflammation after subarachnoid hemorrhage in rats via TLR4/NF-κB pathway. [Abstract]

2025 Oct 27:232:111607. PMID: 41161421
Mol Biol Rep

Study on the mechanism of heterogeneous tumor-associated macrophages in three subtypes of breast cancer through the integration of single-cell RNA sequencing and in vitro experiments. [Abstract]

2024 Jun 1;51(1):720. PMID: 38824268
Research Square Preprint

2024 Dec 16.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (219.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1951 mL

10.9757 mL

21.9515 mL

5 mM

0.4390 mL

2.1951 mL

4.3903 mL

10 mM

0.2195 mL

1.0976 mL

2.1951 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.49 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Pasupuleti BG, et al. 1,2,3-Triazole tethered 1,2,4-trioxanes: Studies on their synthesis and effect on osteopontin expression in MDA-MB-435 breast cancer cells. Eur J Med Chem. 2020 Jan 15;186:111908. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1951 mL	10.9757 mL	21.9515 mL	54.8787 mL
	5 mM	0.4390 mL	2.1951 mL	4.3903 mL	10.9757 mL
	10 mM	0.2195 mL	1.0976 mL	2.1951 mL	5.4879 mL
	15 mM	0.1463 mL	0.7317 mL	1.4634 mL	3.6586 mL
	20 mM	0.1098 mL	0.5488 mL	1.0976 mL	2.7439 mL
	25 mM	0.0878 mL	0.4390 mL	0.8781 mL	2.1951 mL
	30 mM	0.0732 mL	0.3659 mL	0.7317 mL	1.8293 mL
	40 mM	0.0549 mL	0.2744 mL	0.5488 mL	1.3720 mL
	50 mM	0.0439 mL	0.2195 mL	0.4390 mL	1.0976 mL
	60 mM	0.0366 mL	0.1829 mL	0.3659 mL	0.9146 mL
	80 mM	0.0274 mL	0.1372 mL	0.2744 mL	0.6860 mL
	100 mM	0.0220 mL	0.1098 mL	0.2195 mL	0.5488 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

OPN-IN-1

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) OPN-IN-1

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

OPN-IN-1

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) OPN-IN-1

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

OPN-IN-1 Related Classifications

HY-146064 Related Classifications